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Abstract—Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However,
many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis,
myocardial infarction, and death. This advisory stresses the importance of 12months of dual antiplatelet therapy after placement of a drug-eluting
stent and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective
surgery for 1 year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients
with drug-eluting stents. (J Am Coll Cardiol 2007;49:734–9)
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After placement of a bare-metal stent, thienopyridines(clopidogrel [Plavix, sanofi-aventis, Bridgewater, NJ] or
ticlopidine [Ticlid, Hoffmann-La Roche Inc, Nutley, NJ]), in
combination with aspirin therapy, have been shown to dra-
matically reduce the incidence of early major adverse cardiac
events after stent placement compared with aspirin alone or in
combination with warfarin (Table 1) (1). In addition, the use
of thienopyridine therapy plus aspirin for up to 1 year after
non–ST-segment–elevation acute coronary syndromes is
known to decrease the incidence of ischemic cardiovascular
events and is recommended in the American College of
Cardiology/American Heart Association practice guidelines
for the treatment of patients undergoing percutaneous coro-
nary intervention and for the medical treatment of patients
with non–ST-segment–elevation acute coronary syndromes
(2– 4). Despite these benefits, antiplatelet therapy is some-
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times prematurely discontinued within the first year after
stent implantation, either by the patient or by a healthcare
provider who may not realize these benefits or the potentially
severe consequences of antiplatelet therapy cessation. The
leading adverse event associated with early antiplatelet dis-
continuation is stent thrombosis, and the majority of these
events lead to acute myocardial infarction (MI) or death.
Therefore, the American Heart Association, working with the
American College of Cardiology, the Society for Cardiovas-
cular Angiography and Interventions, the American College
of Physicians, the American College of Surgeons, and the
American Dental Association, commissioned this advisory to
emphasize the potential complications of premature discon-
tinuation of thienopyridine therapy and to address potential
strategies to minimize this occurrence.
Dual Antiplatelet Therapy for Prevention
of Ischemic Cardiovascular Events and
Stent Thrombosis
Current American College of Cardiology/American Heart
Association/Society for Cardiovascular Angiography and In-
terventions recommendations for the prevention of stent
thrombosis after coronary stent implantation state that, at a
minimum, patients should be treated with clopidogrel 75 mg
and aspirin 325 mg for 1 month after bare-metal stent
implantation, 3 months after sirolimus drug-eluting stent
(DES) implantation, 6 months after paclitaxel DES implan-
tation, and ideally, up to 12 months if they are not at high risk
for bleeding (3). These recommendations were based on the
antiplatelet regimen used in trials that were conducted to
obtain US Food and Drug Administration approval (low-risk
lesions in low-risk patients) and the anticipated time it takes
for the metal stent struts to become adequately endotheli-
alized to reduce the risk of stent thrombosis. However, DESs
are now being used in high-risk lesions, and reports have
suggested that they may be associated with delayed (or
absent) endothelialization (5,6), localized hypersensitivity
reactions (7,8), and late stent thrombosis.
Stent thrombosis most commonly occurs in the first month
after stent implantation, and in this interval, it is referred to as
“subacute stent thrombosis.” However, numerous cases of
“late” stent thrombosis, particularly in patients who have
been treated with DES, have been described as occurring
months or even years after stent implantation (19 –21). In the
majority of cases, stent thrombosis is a catastrophic event,
resulting in life-threatening complications. In a pooled anal-
ysis of 6 trials and registries from the 1990s, the incidence of
death or MI associated with angiographically documented
stent thrombosis was found to be 64.4% (14). Mortality rates
due to presumed or documented stent thrombosis range from
20% to 45% (19 –21).
In the current era of dual antiplatelet therapy, the average
reported occurrence of subacute stent thrombosis is 1%
(16 –22). The timing of thrombosis appears to be delayed in
DES. Late (1 to 12 months) stent thrombosis was not readily
apparent with bare-metal stents yet was reported to occur in
0.19% of patients in a large DES registry (18). Predictors of
late stent thrombosis have included stenting of small vessels,
multiple lesions, long stents, overlapping stents, ostial or
bifurcation lesions, prior brachytherapy, suboptimal stent
result (underexpansion, malapposition, or residual dissec-
tion), low ejection fraction, advanced age, diabetes mellitus,
renal failure, acute coronary syndrome, and premature dis-
continuation of antiplatelet agents (Table 2) (9,13,18 –21).
On December 7–8, 2006, the US Food and Drug Admin-
istration convened an advisory panel meeting to discuss stent
thrombosis and the overall safety of DES (23). They con-
cluded that there appears to be a numerical excess of late stent
thrombosis with DES, but the magnitude is uncertain; and the
off-label use of DES, as with bare-metal stents, is associated
with increased risk when compared with on-label use. The
TABLE 1. After Bare-Metal Stent Placement, Aspirin Plus Thienopyridine Reduces Cardiac Events
Compared With Aspirin Alone or With Oral Antithrombins
Study No. of Pts Studied No. of Pts Treated
MACE, %*
ASA Thienopyridine ASA Warfarin ASA Alone P
ISAR (32) 517 626 1.6 6.2    0.01
FANTASTIC (33) 473 485 5.7† 8.6†    0.37
STARS (34) 1653 1965 0.5 2.7 3.6 0.0001
MATTIS (35) 350 350 5.6 11.0    0.07
Hall et al (36) 226 358 0.8    3.9 0.1
MACE indicates major adverse cardiovascular events; Pts, patients; ASA, aspirin; ISAR, Intracoronary Stenting and Antithrombotic
Regimen trial; FANTASTIC, Full ANTicoagulation versus ASpirin TIClopidine after stent implantation; STARS, STent Anticoagulation
Regimen Study; and MATTIS, Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting.
*Cardiac death, acute MI, or repeat target-vessel revascularization at 30 days (except for the FANTASTIC study).
†Death, MI, or stent occlusion at 6 weeks.
Adapted from ten Berg et al (1).
TABLE 2. Predictors of DES Thrombosis: Considerations for
Prolonged Dual Antiplatelet Therapy
Clinical Angiographic
Advanced age Long stents
Acute coronary syndrome Multiple lesions
Diabetes Overlapping stents
Low ejection fraction Ostial or bifurcation lesions
Prior brachytherapy Small vessels
Renal failure Suboptimal stent results
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panel also agreed that, in the future, new DES studies should
have longer follow-up, enroll greater numbers of patients, and
include stent thrombosis as a study end point. The advisory
panel concurred with the joint clinical practice guideline
recommendation (3) for 12 months of dual antiplatelet ther-
apy after placement of a drug-eluting stent in patients who are
not at high risk of bleeding. However, they agreed that a large
randomized trial looking specifically at appropriate duration
of dual antiplatelet therapy is needed.
Premature Thienopyridine
Discontinuation and Stent Thrombosis
The premature discontinuation of thienopyridine therapy is
associated with a marked increase in the risk of stent
thrombosis and is the leading independent predictor for stent
thrombosis in multivariate analyses. Although the number of
actual stent thromboses reported in individual studies is
modest, the findings are noteworthy.
In a large observational cohort study of patients treated
with DES, stent thrombosis occurred in a striking 29% of
patients in whom antiplatelet therapy was discontinued pre-
maturely (9). This discontinuation of antiplatelet therapy was
associated with a hazard ratio of 161 (95% confidence
interval 26 to 998) for the occurrence of subacute stent
thrombosis and a hazard ratio of 57 (95% confidence interval
15 to 220) for the occurrence of late (30 days) stent
thrombosis.
In a single-site study of 652 patients treated with sirolimus
DES, premature discontinuation of clopidogrel was associ-
ated with an 30-fold greater risk of stent thrombosis, with
25% of patients who discontinued clopidogrel therapy
within the first month suffering stent thrombosis (17). Park et
al (13) reported on 1911 consecutive patients with DES
followed up for a median of 19.4 months. Five (7.8%) of 64
patients with premature interruption of aspirin, clopidogrel,
or both experienced stent thrombosis.
Spertus and colleagues (19) published an analysis from the
PREMIER (Prospective Registry Evaluating Myocardial In-
farction: Events and Recovery) registry of 500 patients with
acute MI treated with DES. The mortality rate over the next
11 months of those who stopped thienopyridine therapy was
7.5% compared with 0.7% in those who had not stopped
therapy (hazard ratio 9.0, P0.0001). Although the rates of
stent thrombosis were not reported, it is reasonable to
presume that many of the deaths were related to coronary
artery disease.
Pfisterer et al (20) randomized 746 patients (1133 lesions)
to DES versus bare-metal stents. All patients received dual
antiplatelet therapy for 6 months, after which aspirin alone
was continued. At 30 days, rates of death or nonfatal MI were
lower in the DES group (2.0% versus 4.69%, P0.05);
however, after discontinuation of clopidogrel at 6 months,
late stent thrombosis (2.6% versus 1.3%) and death or
nonfatal MI (4.9% versus 1.3%) occurred more frequently in
the DES group.
Similarly, Eisenstein et al (21) reported an observational
study in 4666 patients with follow-up at 6, 12, and 24 months
after stenting. In patients treated with bare-metal stents,
continued use of clopidogrel did not influence death or MI
rates between 6 and 24 months. Conversely, in DES patients,
extended use of clopidogrel at 6, 12, and 24 months was
associated with reduced death or death/MI rates at all time
intervals.
Stent Thrombosis After
Noncardiac Surgery
Several reports have specifically described incidents of stent
thrombosis that occurred after the discontinuation of anti-
platelet therapy for noncardiac surgery among patients re-
cently treated with coronary stents (24 –26). Kaluza et al (25)
reported on 40 patients treated with bare-metal stents who
underwent noncardiac surgery within 6 weeks of stent im-
plantation. Seven patients had an MI, of which 6 were fatal.
Stent thrombosis was presumed to be the cause of all MIs. In
5 of 7 cases, thienopyridine therapy (ticlopidine) had been
withheld before surgery. In a similar analysis of 47 patients
who underwent noncardiac surgery within 90 days of bare-
metal stent implantation, 6 of the 7 patients in whom
thienopyridine therapy was discontinued died “in a manner
suggestive of stent thrombosis” (26).
Factors Related to Premature
Cessation of Thienopyridine Therapy
Premature cessation of thienopyridine may occur for several
different reasons. The cost of clopidogrel (approximately $4
daily) has been cited as one reason patients discontinue (or do
not renew) their therapy (27). It is unclear whether the
introduction of modestly lower-cost generic clopidogrel will
significantly affect this issue. In an analysis from the PRE-
MIER registry (19), factors identified with premature discon-
tinuation of thienopyridine therapy included older age, not
having completed high school, not being married, not receiv-
ing discharge instructions for medication use, not being
referred for cardiac rehabilitation, greater likelihood of hav-
ing preexistent cardiovascular disease or anemia, and not
seeking health care because of cost. The study authors
concluded that “additional patient education about the ratio-
nale for and importance of continuing thienopyridine treat-
ment may be needed—particularly for patients with less
formal education.”
Dual antiplatelet therapy is not without risk. Like all
antithrombotic agents, both aspirin and clopidogrel increase
the risk of bleeding compared with placebo. When compared
with aspirin, clopidogrel may be associated with lower risk of
GI bleeding (28). However, when clopidogrel was combined
with aspirin and administered for prolonged duration (up to
28 months), randomized trials demonstrated an absolute
increase (ranging from 0.4% to 1.0%) in major bleeding,
compared with aspirin alone (28).
Antiplatelet therapy may be stopped at the instruction of
physicians, dentists, and other healthcare providers who are
to perform an invasive or surgical procedure on the patient
because of misguided concerns about excessive procedure-
related bleeding. Unfortunately, many patients are routinely
instructed to stop “blood thinners” before such procedures
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without a thorough evaluation of the rationale for such
therapy and without distinction between warfarin and anti-
platelet agents. Many of these procedures (eg, minor surgery,
teeth cleaning, and tooth extraction) can likely be performed
at no or only minor risk of bleeding or could be delayed until
the prescribed antiplatelet regimen is completed. Although
there is a longstanding concern on the part of dental practi-
tioners about the possibility of prolonged bleeding during and
after invasive dental procedures on patients receiving anti-
platelet drugs, a recent prospective study of single tooth
extractions on patients randomized to aspirin versus a placebo
failed to show a statistically significant difference in postop-
erative bleeding (29). Although there are no prospective
studies of invasive dental procedures on patients taking a
thienopyridine alone or in combination with aspirin, there are
also no well-documented cases of clinically significant bleed-
ing after dental procedures, including multiple dental extrac-
tions. Given the relative ease with which the incidence and
severity of oral bleeding can be reduced with local measures
during surgery (eg, absorbable gelatin sponge and sutures)
and the unlikely occurrence of bleeding once an initial clot
has formed, there is little or no indication to interrupt
antiplatelet drugs for dental procedures (30).
The likelihood of increased bleeding and/or an increased
requirement for blood transfusion in patients undergoing
major noncardiac surgery can be inferred from reports of
increased bleeding when cardiac surgery (including off-pump
coronary bypass grafting) is undertaken in patients taking a
thienopyridine drug. Independent documentation of the scope
of this risk of increased bleeding during noncardiac surgery,
however, is not available. If one must discontinue the
thienopyridine drug before major surgery to reduce the risk of
excessive bleeding, consideration should be given to continu-
ing aspirin for its antiplatelet action to mitigate the risk of late
stent thrombosis and to restarting the thienopyridine as soon
as possible. Although some have attempted “bridging” stent
patients with antithrombin agents, there is no evidence of a
benefit of warfarin (Table 1) or other antithrombins, and there
is an increased risk of bleeding (31). Similarly, there are no
data to support the use of “bridging” glycoprotein IIb/IIIa
agents.
Summary and Recommendations
Thienopyridine therapy in combination with aspirin has
become the mainstay antiplatelet treatment strategy for the
prevention of stent thrombosis. Premature discontinuation
of antiplatelet therapy markedly increases the risk of stent
thrombosis, a catastrophic event that frequently leads to
MI and/or death. Factors contributing to premature cessa-
tion of thienopyridine therapy include drug cost, physi-
cian/dentist instructions to patients to discontinue therapy
before procedures, and inadequate patient education and
understanding about the importance of continuing therapy.
To eliminate premature discontinuation of thienopyridine
therapy, this advisory group gives the following
recommendations.
1. Before implantation of a stent, the physician should
discuss the need for dual antiplatelet therapy. In patients
not expected to comply with 12 months of thienopyridine
therapy, whether for economic or other reasons, strong
consideration should be given to avoiding a DES.
2. In patients who are undergoing preparation for percutane-
ous coronary intervention and are likely to require inva-
sive or surgical procedures within the next 12 months,
consideration should be given to implantation of a bare-
metal stent or performance of balloon angioplasty with
provisional stent implantation instead of the routine use of
a DES.
3. A greater effort by healthcare professionals must be made
before patient discharge to ensure patients are properly
and thoroughly educated about the reasons they are
prescribed thienopyridines and the significant risks asso-
ciated with prematurely discontinuing such therapy.
4. Patients should be specifically instructed before hospital
discharge to contact their treating cardiologist before
stopping any antiplatelet therapy, even if instructed to stop
such therapy by another healthcare provider.
5. Healthcare providers who perform invasive or surgical
procedures and are concerned about periprocedural and
postprocedural bleeding must be made aware of the
potentially catastrophic risks of premature discontinuation
of thienopyridine therapy. Such professionals who per-
form these procedures should contact the patient’s cardi-
ologist if issues regarding the patient’s antiplatelet therapy
are unclear, to discuss optimal patient management
strategy.
6. Elective procedures for which there is significant risk of
perioperative or postoperative bleeding should be deferred
until patients have completed an appropriate course of
thienopyridine therapy (12 months after DES implantation
if they are not at high risk of bleeding and a minimum of
1 month for bare-metal stent implantation).
7. For patients treated with DES who are to undergo subse-
quent procedures that mandate discontinuation of thien-
opyridine therapy, aspirin should be continued if at all
possible and the thienopyridine restarted as soon as
possible after the procedure because of concerns about
late-stent thrombosis.
8. The healthcare industry, insurers, the US Congress, and
the pharmaceutical industry should ensure that issues such
as drug cost do not cause patients to prematurely discon-
tinue thienopyridine therapy and to thus incur catastrophic
cardiovascular complications.
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